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ABSTRACT 
The present study is performed by preparation and evaluation of ﬂoating tablets of quetiapine fumigate as model drug for prolongation of gastric residence time. Floating 
effervescent tablets were formulated by various materials like hydroxypropyl methylcellulose HPMC ( K4M , K100M, KE15, PLAIN ) , Sodium CMC, PVPK 30, crospovidone, 
Ethylcellulose, MCC, PGMS, polymers with excipients sodium bicarbonate ,citric acid, lactose, magnesium stearate and talc and evaluated for ﬂoating properties, hardness, 
friability, dissolution, tap density and in vitro drug release studies. The gastro-retentive delivery systems of Quetiapine fumarate were successfully developed in the form of 
hydrodynamically balanced tablets to improve the local action and its bioavailability, which reduces the wastage of drug and ultimately improves the solubility for drugs that 
are less soluble in high pH environment thereby improving h, the patient compliance. 
Key words: Quetiapine fumarate; ﬂoating; gastroretentive; crospovidone; microcrystalline cellulose; Ethylcellulose. 
INTRODUCTION 
Oral  sustained  drug  delivery  system  is  complicated  by  limited 
gastric  residence  time  The  CRDDS  possessing  ability  of  being 
retained in the stomach are called gastro retentive drug delivery 
system (GRDDS) and they can help in optimizing oral controlled 
delivery  of  drugs  having  ‘absorption  window’  by  continuously 
releasing drug prior to absorption window, for prolonged period of 
time.[1-3]  Prolonged  gastric  retention  improves  bioavailability, 
reduces drug waste, and improves solubility for drugs that are less 
soluble in a high pH environment. It has applications also for local 
drug delivery to the stomach and proximal small intestine. Gastro 
retention helps to provide better availability of new products with 
new therapeutic possibilities and substantial benefits for patient 
[4]. The controlled gastric retention of solid dosage forms may be 
achieved  by  the  mechanisms  of  mucoadhesion,  floatation, 
sedimentation,  expansion,  modified  shape  systems  or  by  the 
simultaneous administration of pharmacological agents that delay 
gastric emptying. [5] 
Floating  drug  delivery  systems  offer  important  advantages:  as 
they are less prone to gastric emptying resulting in reduced intra 
and  intersubject  variability  in  plasma  drug  levels,  effective  for 
delivery of drugs with narrow absorption windows, reduced dosing 
and increased patient compliance, reduced C max and prolonged 
drug  levels  above  the  minimum  effective  concentration,  and 
improved safety proﬁle for drugs with side-effects associated with 
high Cmax.[6] As the exterior surface of the dosage form goes 
into  the  solution,  the  gel  layer  is  maintained  by  the  adjacent 
hydrocolloid  layer  becoming  hydrated.[7]  The  air  trapped  in  by 
swollen  polymer  maintains  density  less  than  unity  and  confers 
buoyancy to these dosage forms The hydro dynamically balanced 
system must comply with three major criteria- 
  It must have sufficient structure to form cohesive gel barrier  
  It must maintain an overall specific density lower than that of 
gastric content 
  It should dissolve slowly enough to serve as reservoir for the 
delivery system.8-10 
The aim of present study is to prepare and evaluate floating tablet 
of Quetiapine fumarate based on low density polymer that retains 
the  dosage  form  in  the  stomach  which  provide  an  increased 
gastric  residence  time  resulting  in  prolonged  drug  delivery  in 
gastrointestinal  tract  using  HPMC  K4M,  HPMC  K100M,  HPMC 
KE15  and  Ethyl  cellulose  as  sustain  release  polymers  and  to 
study the various formulation and process variables that ultimately 
affects the drug   release.  The selection and optimization of  
 
polymer  concentration,  type  of  filler  and  amount  of  low  density 
polymer that has pronounced effect on tablet properties and drug 
release  profile  as  well  as  buoyant  properties  of  the  
formulations.[11]  
The low bioavailability is owing to the rapid biotransformation in 
the liver with less biological half life of 6 h [12]. The short half life, 
poor bioavailability and faster solubility in acidic medium
5 make it 
a suitable for gastroretentive drug delivery system.  
EXPERIMENTAL 
Materials 
Quetiapine  fumarate  antipsychotic  drug  was  received  as  a  gift 
sample from Micro Lab. Ltd., India. The other ingredients used in 
the  preparation  like  Ethyl  cellulose  (Coating  agent,  viscosity 
enhancer),  Hydroxypropylmethylcellulose  (Tablet  binder,  tablet 
filler, film former), Microcrystalline cellulose (Diluent, disintegrate, 
lubricant),  Polyvinyl  pyrrolidone  (Pharmaceutical  aid),  Lactose 
(Organic  diluents),  Sodium  bicarbonate  (Alkalizing  agent, 
therapeutic  agent),  Pregelatinized  maize  starch  (Tablet 
disintegrator.  Diluents),  Cross  Povidone  (Dissolution  aid, 
disintegrating  agent),  Citric  acid  (Acidifying  agent,  Antioxident, 
Buffering  agent),  Sodium  carboxy  methyl  cellulose  (Extended 
release  matrix,  drug  encapsulator),  Magnesium  stearate 
(Lubricant), Talc (Glidant, anti-cackling agent), were of analytical 
grade. 
METHODS 
Preformulation  studies  were  performed  on  the  drug,  which 
included melting point determination, solubility and compatibility 
studies. The standard calibration curve for Quetiapine fumarate is 
prepared by using UV spectrophotometer. 
PREPARATION  OF  GASTRO  RETENTIVE  FLOATING 
TABLETS 
Floating tablets containing Quetiapine fumarate were prepared by 
direct  compression  technique  using  variable  concentrations  of 
HPMC  K4M,  HPMC  K100M,  KE15  and  Ethyl  cellulose  with 
sodium bicarbonate. Different tablet formulation were prepared by 
direct  compression  method  [13].All  the  powders  were  passed 
through 60 mesh sieve the required qty. of drug and lower density 
polymer  were  mixed  geometrically  and  then  tablets  are 
compressed in compression machine at specified pressure with 
10 mm round punch. (Table no: 1) 
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Table 1: Ingredients. 
INGREDIENTS  F1  F2  F3  F4  F5 
Drug(Quetiapine fumarate)  25  25  25  25  25 
ethyl cellulose  20  -  20  20  20 
Hydroxypropylmethylcellulose(ke15)  60  0  0  0  0 
Hydroxypropylmethylcellulose(k100m)  0  60  0  60  0 
Hydroxypropylmethylcellulose(k4m)  0  0  60  0  0 
Hydroxypropylmethylcellulose(plain)  0  0  0  0  60 
Microcrystalline cellulose  20  20  20  20  20 
Polyvinyl pyrrolidone(k30)  25  25  25  25  25 
Lactose  20  20  35  35  35 
Sodium bicarbonate  100  100  100  100  100 
Pregelatinized maize starch  20  20  -  -  - 
Cross Povidone  -  -  20  20  20 
Citric acid  15  15  -  -  - 
Sodium carboxy methylcellulose  -  20  -  -  - 
Magnesium stearate  10  10  10  10  10 
Talc  10  10  10  10  10 
Swelling index (water uptake) study 
Polymer  matrices  representing  swellable  matrix  drug  delivery 
systems  are  porous  in  nature.  When  these  matrices  come  in 
contact with water or aqueous gastrointestinal fluid, the polymer 
absorbs the water and undergoes swelling or hydration. The rapid 
formation  of  a  viscous  gel  layer  upon  hydration  suggests  that 
swelling is associated with polymer chain relaxation with volume 
expansion.  The  liquid  diffuses  through  the  polymer  matrix  at  a 
constant velocity, and the rate of diffusion of the liquid and that of 
macromolecular relaxation of the polymer are almost of the same 
magnitude  or,  possibly,  the  rate  of  diffusion  of  the  liquid  is 
relatively higher than that of relaxation of the polymer segment. 
[14-16] 
This mechanism gives the idea regarding the water uptake study 
of various grades of polymer. This phenomenon is attributes to 
that  the  swelling  is  maximum  due  to  water  uptake  and  then 
gradually decreased due to erosion. Swelling measurement was 
performed separately in order to collect on the basis of weight 
increase over time. The swelling is due to presence of hydrophilic 
polymer,  which  gets  wetted  and  allows  water  uptake  leads  to 
increase in its weight. 
 
 
In Vitro dissolution studies 
The release rate of Quetiapine fumarate from floating tablets was 
determined using The United States Pharmacopoeia (USP) XXIV 
dissolution testing apparatus II (paddle method). The dissolution 
test was performed using 900 ml of 0.1 N HCl, at 37 ± 0.5°C and 
50 rpm. A sample (5 ml) of the solution was withdrawn from the 
dissolution apparatus hourly for 8 hours, and the samples were 
replaced with fresh dissolution medium. The samples diluted to a 
suitable  concentration  with  0.1N  HCl.  Absorbance  of  these 
solutions  was  measured  at  254  nm  using  a  Simbazu  UV-Vis 
double beam spectrophotometer 1700. Cumulative percentage of 
drug release was calculated using the equation obtained from a 
standard curve.[17]
 
RESULTS AND DISCUSSION 
To identify the presence of pure drug IR spectra for Quetiapine 
fumarate  and  formulated  tablets  were  recorded  in  a  Fourier 
transform infrared spectrophotometer in which the IR spectrum of 
pure  drug  (Figure  1)  was  found  to  be  similar  to  the  standard 
spectrum  of  Quetiapine  fumarate  (Figure  2).  The  pure  drug 
Quetiapine fumarate was scanned over a range 200-300 nm to 
determine its max.[18-20] The peak was observed at 254 nm in 
UV  spectrophotometer  (Table  2)  (Figure  3)  and  the  standard 
calibration  curve  obtained  conforms  the  identification  of 
Quetiapine fumarate in 0.1N HCL. 
 
Fig. 1: IR spectrum of pure Quetiapine fumarate. 
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Fig 2: IR spectrum of Quetiapine fumarate Formulation 
Table 2: Calibration Curve 
SNO  CONCENTRATION(UG)  ABSORBANCE 
 1.   10   0.314 
 2.   20  0.572 
 3.   30  0.905 
 4.   40  1.266 
 5.   50  1.6 
 6.   60  1.926 
 
Figure No: 3 Calibration Curve. 
The  preformulation  studies  like  melting  point  determination  of 
Quetiapine fumarate was found to be in the range of 160-170
0C to 
value as reported in literature,[21] thus indicating purity of the drug 
sample and the drug has also been proved to have good solubility 
properties.  The  prepared  tablets  were  evaluated  for  pre-
compression parameters like bulk density, tapped densisity, angle 
of  repose  and  post-compression  parameters  like  hardness, 
friability,  thickness,  weight  variation  [22]  which  proved  that  the 
tablets are with sufficient hardness and good mechanical strength. 
The formulated tablets were also evaluated for floating lag time 
and total floating time. 
Table  3  shows  the  results  obtained  for  angle  of  repose,  bulk 
density  and  tapped  density  of  all  the  formulations.  The  values 
were found to be in the range of 23
0 76' to 28
0.22'. All formulations 
showing angle of repose within 30
0, indicates a good flow property 
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of  the  granules.  [23]  The  loose  bulk  density  and  tapped  bulk 
density  for  all  the  formulations  varied  from0.5840  gm/cm
3  to 
0.7632gm/cm
3 and 0.7069gm/cm
3 to 0.8904gm/cm
3 respectively. 
The values obtained lies within the acceptable range and not large 
differences  found  between  loose  bulk  density  and  tapped  bulk 
density. This result helps in calculating the % compressibility of 
the powder. The thickness of the tablets was measured by using 
vernier callipers [24] by picking the tablets randomly. The mean 
values are shown in Table 4. The values are almost uniform in all 
formulations. Thickness was found in the range of 4.5 mm to 5.0 
mm.  Hardness  test  was  performed  by  Monsanto  hardness 
tester.[25]  Hardness  was  found  to  be  within  4.5  kg/cm  to  5.1 
kg/cm. The hardness of all the formulations was almost uniform in 
specific  method  and  possesses  good  mechanical  strength  with 
sufficient hardness. Friability tests approve that all Formulations 
possess good mechanical strength. All the tablets passed weight 
variation  test  as  the  %  weight  variation  was  within  the 
pharmacopoeia limits of 10 %. The weight of all the tablets was 
found to be uniform.  
The time taken for dosage form to emerge on surface of medium 
called Floating Lag Time (FLT) or Buoyancy Lag Time (BLT). The 
in  vitro  buoyancy  was  determined  by  floating  lag  time  method 
described by Dave B.S. The tablets were placed in 250 ml beaker 
containing 0.1 N HCl. The time required for the tablets to rise to 
the surface and float was determined as floating lag time [26]. The 
time between introduction of dosage form and its buoyancy in 0.1 
N HCl and the time during which the dosage form remain buoyant 
were measured. Floating lag time of F1 –F5 was in the range of 
1min 2sec -1min 8sec, F2 Shows good floating lag time of 1min 2 
sec. (Table 5) Total duration of time by which dosage form remain 
buoyant  is  called  Total  Floating  Time  (TFT).All  formulations  a 
show TFT more than 10 hrs and F2 shows good total floating time 
that is more than 12 hrs. 
In-vitro water uptake studies are of great significance as variation 
in  water  content  causes  a  significant  variation  in  mechanical 
properties  of  formulations  [27]  (Table  6).  The  capacity  of  the 
formulation to take up water is an important intrinsic parameter of 
the polymeric system in consideration to the release of the drug. 
Invitro drug release study was performed using USP II (paddle) 
dissolution test apparatus at 50 rpm using 900 ml of 0.1N HCL 
maintained  at  37
0  ±  0.5
0C  as  dissolution  medium.  The  results 
were shown in table 7. Among the five formulations F1 to F3 have 
released  85  to  97%  drug  in  8  hours,  whereas  F4  to  F6 
formulations have released 94 to 99% drug in 8 hours.F2 Shows 
comparatively  similar  drug  release  rate  with  marketed  drug. 
(Figure 5) 
Table 3: Precompression Parameters. 
parameters  F1  F2  F3  F4  F5 
Bulk Density 
(g/cc) 
0.7632  0.7241  0.5840  0.6066  0.6241 
Tapped Density 
(g /cc) 
0.8904  0.8119  0.7069  0.7800  0.7645 
Angle of 
Repose (θ) 
25.35  24.33  27.70  28.22  23.76 
Table 5: Floating lag Time and Total floating time of designed formulations 
 
   
 
 
 
 
 
 
 
 
Table 6: Percent (%) of swelling index.
Time 
(min) 
% Swelling index 
F1  F2  F3  F4  F5 
0  0  0  0  0  0 
15  38  38  39.6  32.14  40.38 
30  53.38  51.9  49  35.71  51.92 
60  67.73  71.15  64.15  55.35  69.23 
120  84.61  84.6  84.9  76.8  88.46 
180  103  101.9  105.66  91.07  119.2 
240  115.38  119.23  128.3  101.78  123.07 
300  121.15  126.9  132  108.92  134.61 
360  134.61  136.53  137.7  116  150 
420  138.46  142.3  143.39  123.21  153.84 
480  145.84  146.84  150.05  121.65  160.35 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO  FORMULATION  FLOATINGLAG 
TIME(MIN) 
TOTAL 
FLOATING 
TIME(TFT) 
1  F1  1.3  >11 hrs. 
2  F2  1.2  >12 hrs. 
3  F3  1.5  >10 hrs. 
4  F4  1.7  >11 hrs. 
5  F5  1.8  >10 hrs. Prathyusha et al                                                                                                      Mintage journal of Pharmaceutical & Medical Sciencesǀ10-15 
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Fig. 4: Percent (%) of Swelling Index. 
 
Table 7: % DRUG RELEASE 
 
Fig 5: Comparative Drug Release Of F1 – F6. 
 
CONCLUSION 
In vitro buoyancy studies were performed for all the formulations, 
F1  to  F5  by  using  0.1  N  HCl  solutions  at  37oC.  All  the 
formulations were floated but F2 shows good floating property that 
is floating lag time of 1min 2sec, which containing 60 mg of HPMC 
K100M, 20 mg of NACMC, and 100 mg of sodium bicarbonate 
and 15mg of citric acid showed total floating time more than (12 
hours) than other formulations.  In vitro  dissolution studies were 
also performed, percentage drug release was found to be 98.18. 
Thus F2 was identified as ideal batch based on its results. Finally, 
it was concluded that HPMC K100M, SCMC, sodium bicarbonate 
and  citric  acid  can  be  successfully  used  in  the  formulation  of 
Quetiapine  fumarate  sustained  release  gastro  retentive  floating 
drug delivery system. Gastric retention time can be increased for 
a  drug  like  Quetiapine  fumarate,  by  formulating  it  in  a  floating 
dosage  form,  which  enhances  the  absorption  of  Quetiapine 
fumarate in the initial part of small intestine and hence giving the 
desired pharmacological effect. And the so developed formulation 
holds promising for other drugs, which has an absorption window 
in stomach and upper part of the small intestine. 
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